DR. CAROL WEISS, M.D.
Osteopathic Medicine at Wisconsin Ave, Bethesda, MD
License number
Maryland D0047035
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
8901 Wisconsin Ave, Bethesda, MD 20889
Phone
(301) 402-3190
(301) 718-7355
(301) 718-7355
Personal information
See more information about CAROL WEISS at radaris.comName
Address
Phone
510 Pinehurst Cir APT T3, Westminster, MD 21158
445 Rogers Ave, Glen Burnie, MD 21060
4812 Hornbeam Dr, Rockville, MD 20853
3711 Federal Ln, Abingdon, MD 21009
510 Pinehurst Cir, Westminster, MD 21158
Organization information
See more information about CAROL WEISS at bizstanding.comCarol Weiss MD
8901 Rockville Pike, Bethesda, MD 20889
Industry:
Internist
Phone:
(301) 402-3190 (Phone)
Carol Diane Weiss
Professional information
Dr. Carol Weiss, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
8901 Wisconsin Ave, Bethesda 20889
(301) 402-3190 (Phone)
(301) 402-3190 (Phone)
Certifications:
Internal Medicine, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1984
St Vincents Hosp Med Ctr
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1984
St Vincents Hosp Med Ctr
Methods Of Eliciting Broadly Neutralizing Antibodies Targeting Hiv-1 Gp41
US Patent:
2011014, Jun 16, 2011
Filed:
Oct 30, 2007
Appl. No.:
11/928612
Inventors:
Carl T. Wild - Gaithersburg MD, US
Carol D. Weiss - Bethesda MD, US
Carol D. Weiss - Bethesda MD, US
Assignee:
Panacos Pharmaceuticals, Inc. - Gaithersburg MD
GOVERNMENT OF THE U.S., REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES - WASHINGTON DC
GOVERNMENT OF THE U.S., REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES - WASHINGTON DC
International Classification:
A61K 39/42, A61K 39/21, C07K 16/10, C07H 21/04, C12N 15/63, C12N 5/10, A61P 37/04, A61P 31/18
US Classification:
4241481, 4242081, 53038835, 5303894, 4241601, 536 2372, 4353201, 435325
Abstract:
The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.
Methods Of Eliciting Broadly Neutralizing Antibodies Targeting Hiv-1 Gp41
US Patent:
7311916, Dec 25, 2007
Filed:
Sep 10, 2003
Appl. No.:
10/660206
Inventors:
Carl T. Wild - Gaithersburg MD, US
Carol D. Weiss - Bethesda MD, US
Carol D. Weiss - Bethesda MD, US
Assignee:
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC
Panacos Pharmaceuticals, Inc. - Gaitherburg MD
Panacos Pharmaceuticals, Inc. - Gaitherburg MD
International Classification:
A61K 39/21, A61K 39/385
US Classification:
4241881, 42419611
Abstract:
The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.